Get it on Google Play

FDA extends Capricor's deramiocel review deadline to November 2026

August 24, 2026 9:25 AM EDT Send to a Friend
Capricor Therapeutics (NASDAQ: CAPR) announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login